AbbVie in position to become largest pharma by 2028, narrowly edging out Roche — report
Thanks to the success of its Covid-19 vaccine Comirnaty, Pfizer currently holds the top spot in Evaluate Pharma’s ranking of pharma companies by sales — but not for long, according to analysts.
A new Evaluate Pharma report predicts that Pfizer will drop down four spots by 2028, with AbbVie pegged to become the top-selling pharma with an estimated $65.7 billion in sales.
Despite approaching a fast-approaching patent cliff for Humira, AbbVie has candidates in the pipeline to replace that lost revenue, such as Skyrizi, Rinvoq and Venclexta, according to analysts. CEO Rick Gonzalez picked up on that note earlier this year when he predicted Skyrizi and Rinvoq will become Humira’s successors, taking up all of its indications plus atopic dermatitis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.